MedTrace Logo

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

NCT05493618 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2023-01-27

No results posted yet for this study

Summary

This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma.

Conditions

  • Multiple Myeloma, Refractory

Interventions

DRUG

Pembrolizumab

Pembrolizumab 200 mg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).

DRUG

Belantamab mafodotin

Belantamab 2.5 mg/kg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).

DRUG

Dexamethasone

Dexamethasone 40 mg IV q3 weeks (20 mg if patient \>75) until unacceptable toxicity or disease progression for up to 2 years (35 cycles).

Sponsors & Collaborators

Principal Investigators

  • Noa Biran, MD · Division of Hematology and Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-31
Primary Completion
2025-11-30
Completion
2025-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05493618 on ClinicalTrials.gov